Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
This study will evaluate the safety and clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation.
Advanced Solid Tumor
DRUG: MRTX849|DRUG: Palbociclib
Characterize the number of patients with treatment emergent adverse events of the combination regimen in patients with advanced solid tumor malignancies with KRAS G12C mutation., Number of participants with treatment emergent adverse events, 24 months|Evaluate Pharmacokinetics of the combination regimen, Plasma concentration, 24 months|Establish Maximum Tolerated Dose, Number of patients with dose limiting toxicity, 24 months|Evaluate preliminary clinical activity of the combination regimen, Objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST), 24 months
This study will evaluate the pharmacokinetics and preliminary clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation. MRTX849 is an orally available small molecule inhibitor of KRAS G12C and palbociclib is a small molecule inhibitor of CDK 4 and 6.